249 related articles for article (PubMed ID: 15607119)
1. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
Wong CS; Kwok JC; Richardson DR
Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
[TBL] [Abstract][Full Text] [Related]
2. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
3. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
4. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
5. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity.
Mladĕnka P; Kalinowski DS; Haskova P; Bobrovová Z; Hrdina R; Simůnek T; Nachtigal P; Semecký V; Vávrová J; Holeckova M; Palicka V; Mazurová Y; Jansson PJ; Richardson DR
Chem Res Toxicol; 2009 Jan; 22(1):208-17. PubMed ID: 19172757
[TBL] [Abstract][Full Text] [Related]
6. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of a novel oral iron chelator: 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-one.
Pangjit K; Banjerdpongchai R; Phisalaphong C; Fucharoen S; Xie YY; Lu ZD; Hider RC; Srichairatanakool S
J Pharm Pharmacol; 2015 May; 67(5):703-13. PubMed ID: 25627251
[TBL] [Abstract][Full Text] [Related]
8. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
9. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
10. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Richardson DR; Tran EH; Ponka P
Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
[TBL] [Abstract][Full Text] [Related]
11. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Apr; 131(4):306-15. PubMed ID: 9579383
[TBL] [Abstract][Full Text] [Related]
12. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
13. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
14. Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.
Bernhardt PV; Chin P; Sharpe PC; Wang JY; Richardson DR
J Biol Inorg Chem; 2005 Nov; 10(7):761-77. PubMed ID: 16193304
[TBL] [Abstract][Full Text] [Related]
15. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
16. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
17. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
19. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species.
Whiteside DP; Barker IK; Mehren KG; Jacobs RM; Conlon PD
J Zoo Wildl Med; 2004 Mar; 35(1):40-9. PubMed ID: 15193072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
